The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...
The social transmission of pain, for example, is mediated by a pathway involving the brain’s anterior cingulate cortex (ACC) and the nucleus accumbens (NAc), while empathy-based fear is dictated by ...
Now, after 25 years of research, scientists at Vertex Pharmaceuticals figured out how to block this same pain pathway with suzetrigine, leading to a new pain medication for the FDA to approve.
A common genetic pathway may account for increased risk for atherosclerotic disease in patients with chronic widespread musculoskeletal pain.
The study reveals how solvent molecules can modulate pain signals, offering a potential pathway for a safer ... it suppressed pain signal transmission and achieved effective analgesia.
In a new study, scientists at the Leibniz Institute for Neurobiology (LIN) and University Hospital Magdeburg demonstrated ...